治疗复发性外阴阴道假丝酵母菌病新药:奥特康唑
A new drug in treatment of recurrent vulvovaginal candidiasis:oteseconazole
周琳 1王磊 1邢曼 1杨涛2
作者信息
- 1. 青岛市第三人民医院,山东青岛 266041
- 2. 甘肃省妇幼保健院,甘肃兰州 730050
- 折叠
摘要
复发性外阴阴道假丝酵母菌病(RVVC)是困扰女性的常见复发性、难治性疾病之一.奥特康唑是由美国Mycovia制药公司研发的口服靶向真菌甾醇14α-去甲基化酶(CYP51)的唑类金属酶抑制剂,于2022年4月26日在美国获批上市,是第一个用于治疗RVVC的药物.临床试验表明,奥特康唑对RVVC疗效显著,安全性较好.
Abstract
Recurrent vulvovaginal candidiasis(RVVC)is one of the common recurrent and refractory diseases that troubles women.Oteseconazole,the first drug for the treatment of RVVC,is an oral azole metallic enzyme inhibitor targeting fungal sterol 14 α-demethylase(CYP51)developed by Mycovia Pharmaceuticals,Inc.,and was approved for sale in the United States on April 26,2022.Clinical trials have shown that oteseconazole has a significant therapeutic effect on RVVC with minimal adverse reactions.
关键词
奥特康唑/外阴阴道假丝酵母菌病/临床研究Key words
oteseconazole/vulvovaginal candidiasis/clinical study引用本文复制引用
出版年
2024
NETL
NSTL
万方数据